company background image
BGLC

BioNexus Gene Lab OTCPK:BGLC Stock Report

Last Price

US$1.07

Market Cap

US$185.9m

7D

-5.3%

1Y

-9.3%

Updated

05 Oct, 2022

Data

Company Financials
BGLC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends0/6

BGLC Stock Overview

BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia.

BioNexus Gene Lab Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for BioNexus Gene Lab
Historical stock prices
Current Share PriceUS$1.07
52 Week HighUS$2.25
52 Week LowUS$0.16
Beta0.54
1 Month Change-7.76%
3 Month Change-6.14%
1 Year Change-9.32%
3 Year Changen/a
5 Year Changen/a
Change since IPO160.98%

Recent News & Updates

Shareholder Returns

BGLCUS Medical EquipmentUS Market
7D-5.3%6.4%4.4%
1Y-9.3%-25.7%-18.2%

Return vs Industry: BGLC exceeded the US Medical Equipment industry which returned -25.7% over the past year.

Return vs Market: BGLC exceeded the US Market which returned -18.2% over the past year.

Price Volatility

Is BGLC's price volatile compared to industry and market?
BGLC volatility
BGLC Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: Insufficient data to determine BGLC's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine BGLC's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201730Sook Yeohhttps://www.bionexusgenelab.com

BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming.

BioNexus Gene Lab Corporation Fundamentals Summary

How do BioNexus Gene Lab's earnings and revenue compare to its market cap?
BGLC fundamental statistics
Market CapUS$185.88m
Earnings (TTM)US$262.97k
Revenue (TTM)US$12.34m

708.6x

P/E Ratio

15.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGLC income statement (TTM)
RevenueUS$12.34m
Cost of RevenueUS$10.61m
Gross ProfitUS$1.72m
Other ExpensesUS$1.46m
EarningsUS$262.97k

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.0015
Gross Margin13.95%
Net Profit Margin2.13%
Debt/Equity Ratio0%

How did BGLC perform over the long term?

See historical performance and comparison